Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
Broadly neutralizing antibodies (bNAbs) are promising agents to prevent HIV infection and achieve HIV remission without antiretroviral therapy (ART). As with ART, bNAb combinations are likely needed to cover HIV's extensive diversity. Not all bNAbs are identical in terms of their breadth, poten...
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
Public Library of Science (PLoS)
2022-04-01
|
| Σειρά: | PLoS Computational Biology |
| Διαθέσιμο Online: | https://doi.org/10.1371/journal.pcbi.1010003 |